Article in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 3 institutions in 1 country.
Jarosław WaloryDepartment of Drug Biotechnology and Bioinformatics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland. jwalory@gmail.com.pl.ORCID 0000-0003-2352-2621
Lidia MielczarekDepartment of Drug Biotechnology and Bioinformatics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland. l.mielczarek@nil.gov.pl.
Małgorzata JarończykDepartment of Drug Biotechnology and Bioinformatics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland. mjaronczyk@gmail.com.
Mirosława KoronkiewiczDepartment of Drug Biotechnology and Bioinformatics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland. m.koronkiewicz@nil.gov.pl.
Jerzy KossakowskiWarsaw University of Medicine, Banacha 1, 02-097 Warsaw, Poland. jerzy.kossakowski@wum.edu.pl.
Ryszard BugnoDepartment of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343 Cracow, Poland. bugno@if-pan.krakow.pl.ORCID 0000-0003-3741-674X
Andrzej J BojarskiDepartment of Medicinal Chemistry, Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343 Cracow, Poland. bojarski@if-pan.krakow.pl.ORCID 0000-0003-1417-6333
Zdzisław ChilmonczykDepartment of Drug Biotechnology and Bioinformatics, National Medicines Institute, Chełmska 30/34, 00-725 Warsaw, Poland. z.chilmonczyk@nil.gov.pl.
Narodowy Instytut Leków · PLMaj Institute of Pharmacology · PLMedical University of Warsaw · PL
Funding
VALIDATION OF A MULTIPLEXED ASSAY FOR BLADDER CANCER DIAGNOSISR01CA198887 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI ROSSER, CHARLES J · 2016 to 2025
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Oncotoxic Properties of Serotonin Transporter Inhibitors and 5-HT · full record | OpenQuestion